BioSpace News Archive

The companies announced that Dupixent was the first biologic to significantly reduce itch and skin lesions in patients with Prurigo Nodularis in the Phase III trial.

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotech company, announced the presentation of the study design for its phase III trial, COMPOSE, at the ASCO Gastrointestinal Cancers Symposium, held from January 20 – 22, 2022.

Our strong 2021 performance and confident growth outlook for 2022 and beyond reflect the accelerating innovation and expanding capabilities across Optum and UnitedHealthcare,” said Andrew Witty, chief executive officer of UnitedHealth Group.

Professor Charlotte Deane, Ph.D., of the University of Oxford, has joined Exscientia as Chief Scientist of Biologics AI.

PLx Pharma Inc., is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs.

Eluminex Biosciences announced today that it has acquired certain assets and the related global development and commercialization rights for a novel oral therapy, zuretinol acetate (zuretinol), from Retinagenix Holdings, LLC (Retinagenix).

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, and Sermo, a global leader in physician insights, today announced findings from a survey of Sermo physician members that showed two thirds (66%) of doctors surveyed believe psilocybin therapy has potential therapeutic benefit for patients with treatment-resistant depression (TRD).

Recro Pharma, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, announced the appointment of Eduardo Uribe as the company’s head of quality for Recro San Diego.

Dr. Gandara, Professor and Senior Advisor to the Thoracic Oncology Program at University of California Davis, brings deep expertise and strategic vision in cancer drug and biomarker development.